Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bolt Biotherapeutics, Inc. (BOLT : NSDQ)

• Company Description    Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California. Number of Employees: 52

• Price / Volume Information    Yesterday's Closing Price: $5.61 Daily Weekly Monthly 20 Day Moving Average: 23,656 shares Shares Outstanding: 1.92 (millions) Market Capitalization: $10.75 (millions) Beta: 0.92 52 Week High: $15.60 52 Week Low: $5.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.84% -14.61% 12 Week -22.08% -35.96% Year To Date -47.58% -50.06%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 900 CHESAPEAKE DRIVE - REDWOOD CITY,CA 94063 USA ph: 650-665-9295 fax: - sarah.mccabe@sternir.com http://www.boltbio.com

• General Corporate Information    Officers William P. Quinn - President; Chief Executive Officer and Chief Finan Brian O'Callaghan - Chairman Sarah Nemec - Senior Vice President; Finance Laura Berner - Director Kathleen LaPorte - Director Peer Information Bolt Biotherapeutics, Inc. (CORR.) Bolt Biotherapeutics, Inc. (RSPI) Bolt Biotherapeutics, Inc. (CGXP) Bolt Biotherapeutics, Inc. (BGEN) Bolt Biotherapeutics, Inc. (GTBP) Bolt Biotherapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 097702203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 1.92 Most Recent Split Date: 6.00 (0.05:1) Beta: 0.92 Market Capitalization: $10.75 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-6.40 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-23.00 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.23 Price/Cash Flow: - Price / Sales: 1.10 EPS Growth vs. Year Ago Period: -3.57% vs. Previous Quarter: 23.68% Sales Growth vs. Year Ago Period: -76.83% vs. Previous Quarter: -% ROE 03/31/25 - -94.51 12/31/24 - -77.24 09/30/24 - -69.46 ROA 03/31/25 - -59.07 12/31/24 - -51.80 09/30/24 - -48.55 Current Ratio 03/31/25 - 3.13 12/31/24 - 3.20 09/30/24 - 3.16 Quick Ratio 03/31/25 - 3.13 12/31/24 - 3.20 09/30/24 - 3.16 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - -665.56 Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - -665.56 Pre-Tax Margin 03/31/25 - -1,741.26 12/31/24 - -820.78 09/30/24 - -665.56 Book Value 03/31/25 - 24.42 12/31/24 - 29.89 09/30/24 - 37.65 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.48 12/31/24 - 0.40 09/30/24 - 0.21 Debt-to-Capital 03/31/25 - 32.28 12/31/24 - 28.64 09/30/24 - 17.57

Powered by Zacks Investment Research ©